Incyte Corporation | Large-cap | Healthcare
$67.55
-2.12%
| Incyte Stock Comparison:
Incyte vs VertexIncyte vs RegeneronIncyte vs AlnylamIncyte vs Royalty Pharma plcIncyte vs InsmedIncyte vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 4.2B
Gross Profit 3.9B 92.64%
Operating Income 101.3M 2.39%
Net Income 32.6M 0.77%
EPS (Diluted) $0.15

Balance Sheet Metrics

Total Assets 5.4B
Total Liabilities 2.0B
Shareholders Equity 3.4B
Debt to Equity 0.58

Cash Flow Metrics

Operating Cash Flow 162.1M
Free Cash Flow 235.2M

Revenue & Profitability Trend

Incyte Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 4.2B 3.7B 3.4B 3.0B 2.7B
Cost of Goods Sold 312.1M 255.0M 207.0M 151.0M 131.3M
Gross Profit 3.9B 3.4B 3.2B 2.8B 2.5B
Operating Expenses 3.8B 2.8B 2.6B 2.2B 2.8B
Operating Income 101.3M 649.7M 591.6M 600.5M -240.2M
Pre-tax Income 316.6M 834.2M 529.1M 570.4M -232.2M
Income Tax 284.0M 236.6M 188.5M -378.1M 63.5M
Net Income 32.6M 597.6M 340.7M 948.6M -295.7M
EPS (Diluted) $0.15 $2.65 $1.52 $4.27 -$1.36

Income Statement Trend

Incyte Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 3.2B 4.6B 4.1B 3.1B 2.4B
Non-Current Assets 2.2B 2.1B 1.7B 1.8B 1.2B
Total Assets 5.4B 6.8B 5.8B 4.9B 3.6B
Liabilities
Current Liabilities 1.6B 1.2B 1.2B 854.3M 631.2M
Non-Current Liabilities 354.8M 351.9M 313.8M 309.0M 318.5M
Total Liabilities 2.0B 1.6B 1.5B 1.2B 949.6M
Equity
Total Shareholders Equity 3.4B 5.2B 4.4B 3.8B 2.6B

Balance Sheet Composition

Incyte Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 32.6M 597.6M 340.7M 948.6M -295.7M
Operating Cash Flow 162.1M 352.3M 692.9M 658.1M -220.0M
Investing Activities
Capital Expenditures - - - - -
Investing Cash Flow 257.7M -160.2M -709.0K -26.7M -81.6M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -2.1B -55.9M -61.9M -52.4M -61.4M
Free Cash Flow 235.2M 449.0M 892.1M 568.5M -312.0M

Cash Flow Trend

Incyte Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 336.30
Forward P/E 10.95
Price to Book 3.55
Price to Sales 2.95
PEG Ratio 10.95

Profitability Ratios

Profit Margin 0.48%
Operating Margin 20.65%
Return on Equity 0.47%
Return on Assets 2.04%

Financial Health

Current Ratio 2.04
Debt to Equity 1.18
Beta 0.68

Per Share Data

EPS (TTM) $0.20
Book Value per Share $18.93
Revenue per Share $22.13

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
incy 13.0B 336.30 3.55 0.47% 0.48% 1.18
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Alnylam 40.8B - 353.42 -414.62% -11.49% 2,358.26
Royalty Pharma plc 20.3B 14.75 2.30 18.00% 48.26% 77.82
Insmed 20.0B - 193.43 -320.20% -265.93% 1,316.96

Financial data is updated regularly. All figures are in the company's reporting currency.